Insider Trading April 17, 2026 05:03 PM

Insider Purchases at Cartesian Growth Corp III Total $2.06 Million

Pangaea Three-B, LP boosts direct stake as firm and affiliated entities buy shares and warrants across April 15-17, 2026

By Leila Farooq CGCT
Insider Purchases at Cartesian Growth Corp III Total $2.06 Million
CGCT

Entities tied to Cartesian Growth Corp III (CGCT) acquired equity and warrants totaling $2.06 million in mid-April 2026. Purchases included 200,000 Class A ordinary shares and multiple warrant tranches across April 15-17. The stock trades near its 52-week high while InvestingPro flags valuation concerns and low price volatility.

Key Points

  • Affiliated buyers purchased 200,000 Class A ordinary shares between April 15 and April 16, 2026, at prices from $10.324 to $10.327.
  • Pangaea Three-B, LP, controlled by Peter Yu, acquired 100,000 shares on April 15 and 100,000 shares on April 16 and now directly holds 1,471,000 Class A ordinary shares.
  • Warrant purchases occurred across April 15-17: 34,963 warrants at $0.76, 152,100 warrants at $0.86, and 28,522 warrants at $0.90; overall buys totaled $2.06 million. Sectors impacted include equity markets and capital markets activity.

Cartesian Growth Corp III (EXCHANGE:CGCT) registered insider-related purchases totaling $2.06 million during a concentrated window in mid-April 2026. According to transaction details, affiliated parties bought 200,000 Class A ordinary shares between April 15 and April 16, paying between $10.324 and $10.327 per share.


Transaction details

Documents show the share purchases were split evenly: 100,000 Class A ordinary shares were acquired on April 15 and a further 100,000 on April 16. The per-share prices for those transactions ranged narrowly from $10.324 to $10.327. At the time of reporting the stock is quoted at $10.29, which is about 1% below its 52-week high of $10.42.


Purchaser identity and holdings

The buyer of the shares is identified as Pangaea Three-B, LP, a vehicle controlled by Peter Yu. Pangaea Three-B, LP is recorded as purchasing 100,000 shares on April 15 and another 100,000 on April 16. After completing these transactions, the entity directly holds 1,471,000 Class A ordinary shares.


Warrants activity

In addition to the Class A ordinary shares, several warrant purchases were executed across April 15, April 16 and April 17. The reported warrant transactions are:

  • 34,963 warrants purchased on April 15 at $0.76 each;
  • 152,100 warrants purchased on April 16 at $0.86 each;
  • 28,522 warrants purchased on April 17 at $0.90 each.

Market context and analyst notes

Price context provided with the transaction data notes the share price at $10.29, slightly below the 52-week peak of $10.42. InvestingPro commentary included alongside these details characterizes the stock as appearing overvalued at current levels. InvestingPro Tips also indicate the name generally trades with low price volatility, a point highlighted as one of seven additional tips available to subscribers.


Takeaway

The mid-April purchasing activity combined share and warrant acquisitions by affiliated entities, with Pangaea Three-B, LP increasing its direct holding to 1,471,000 Class A ordinary shares. The transactions occurred as the stock traded near its 52-week high and amid an InvestingPro assessment that the company may be overvalued and typically exhibits low price volatility.

Risks

  • Valuation concern: InvestingPro analysis states the stock appears overvalued at current levels, which is a valuation risk for equity investors.
  • Low price volatility: InvestingPro Tips note that the stock generally trades with low price volatility, a factor that can affect trading strategies and liquidity.
  • Narrow margin to peak price: The share price is trading about 1% below its 52-week high of $10.42, an uncertainty for investors monitoring upside relative to recent peaks.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026